IXALTIS is start-up pharmaceutical company specialized in genitourinary and renal diseases.
The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé.
IXALTIS has acquired the rights to three molecules from Sanofi, including its lead compound Litoxetine (IXA-001), and completed a round A of financing in 2016.
IXALTIS has been created to develop these compounds alongside further products acquired through licensing/acquisition in the genitourinary sphere.
The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders.
IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.
IXALTIS possesses key factors of success: a leading compound with strong scientific rationale combined with very encouraging preclinical and clinical data, an experienced team to successfully develop the product, two additional compounds with the potential for a development in other related indications.
« Our company has the objective of becoming a leading developer of innovative pharmaceutical products for treating disorders of the urogenital tract, bringing to the clinic solutions for diseases that affect many people and for which there are few or no satisfactory treatments ».
IXALTIS is member of the Lyonbiopôle.
As a Bio Cluster, Lyonbiopôle is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.